- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01514422
Minocycline for Bipolar Depression
December 6, 2016 updated by: Dan V. Iosifescu, Icahn School of Medicine at Mount Sinai
Minocycline for Bipolar Disorder
The purpose of this study is to evaluate minocycline as a potential treatment for bipolar depression when added to a mood-stabilizing medication.
Minocycline is an antibiotic that is approved for the treatment of infections and acne.
Participation in this research study is expected to last 8 weeks, and includes five outpatient visits.
Study Overview
Detailed Description
Bipolar depression remains the great unmet need in the treatment of bipolar disorder.
Only two treatments have been FDA-approved for the management of acute bipolar depression (the combination of olanzapine and fluoxetine and quetiapine).
Early pilot data suggests the drug minocycline has potent antidepressant effects.
Minocycline is approved by the Food and Drug Administration (FDA) (for acne and bacterial infections), is inexpensive and readily available in generic formulation, and is generally well-tolerated.
This study will examine whether administering the drug minocycline to individuals with bipolar depression over 8 weeks will improve their depressive symptoms.
This study will also offer an option to participate in proton magnetic resonance spectroscopy (1H-MRS) to measure N-Acetylaspartate (NAA) levels in the brain, which are thought to be decreased in bipolar disorder.
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States, 10029
- Icahn School of Medicine at Mount Sinai
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 68 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Meets DSM-IV criteria for Bipolar I Disorder or Bipolar II disorder, depressed phase
- A baseline score of at least 18 on the Montgomery-Asberg Depression Rating Scale (MADRS)
- Participants on mood stabilizer medication for at least two weeks prior to starting the study, and must remain on the treatment during the study
- Able to understand English
Exclusion Criteria:
- DSM-IV diagnosis of Bipolar NOS, Cyclothymia, or Schizoaffective Bipolar type
- Pregnant women or women of child bearing potential who are not using a medically accepted means of contraception (defined as oral contraceptive pill or implant, condom, diaphragm, spermicide, IUD, s/p tubal ligation, partner with vasectomy)
- Serious suicide or homicide risk
- Unstable medical illness including cardiovascular, hepatic, renal, respiratory, endocrine, neurological, or hematological disease
- Clinical or laboratory evidence of hypothyroidism; if maintained on thyroid medication must be euthyroid for at least 1 month before visit 1
- Drug/alcohol dependence within past 30 days, or current substance use disorder that requires detoxification
- Current use of minocycline or history of anaphylactic reaction or intolerance to minocycline
- Primary clinical diagnosis of antisocial or borderline personality disorder
- Patients with metallic foreign bodies or claustrophobia will be excluded from the MRS component
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Minocycline
All subjects will be given minocycline over 8 weeks
|
Minocycline 100 to 300mg per day for 8 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Scores on the Montgomery-Asberg Depression Rating Scale (MADRS)
Time Frame: baseline and week 8
|
Measured at baseline and week 8.
The MADRS-S has 10-items which are based on mood symptoms over the past 7 days.
Each items is scored 0 (normal) to 6 (severe depression) with overall score ranges from 0 (normal) to 60 (severe depression).
|
baseline and week 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in N-acetylaspartate (NAA), as Measured by 1H-MRS Scan
Time Frame: baseline and week 8
|
Measured at baseline and week 8
|
baseline and week 8
|
Changes in Young Mania Rating Scale (YMRS)
Time Frame: baseline and week 8
|
Measured at baseline and week 8.
The YMRS is an 11-item questionnaire to measure the severity of manic symptoms.
7 items are scored 0-4 and the other 4 items are scored 0-8, with overall score range from 0 (normal) to 60 (severe mania).
|
baseline and week 8
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Dan V Iosifescu, MD, MSc, Icahn School of Medicine at Mount Sinai
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2011
Primary Completion (ACTUAL)
August 1, 2013
Study Completion (ACTUAL)
August 1, 2013
Study Registration Dates
First Submitted
January 10, 2012
First Submitted That Met QC Criteria
January 20, 2012
First Posted (ESTIMATE)
January 23, 2012
Study Record Updates
Last Update Posted (ESTIMATE)
January 30, 2017
Last Update Submitted That Met QC Criteria
December 6, 2016
Last Verified
December 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GCO 11-0432
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bipolar Depression
-
University Health Network, TorontoCompletedBipolar Disorder | Bipolar Depression | Bipolar I Depression | Bipolar II DepressionCanada
-
Brigham and Women's HospitalRecruitingDepression | Bipolar Disorder | Bipolar Depression | Major Depressive Episode | Bipolar I Depression | Bipolar II DepressionUnited States
-
Forest LaboratoriesGedeon Richter Ltd.CompletedDepression, BipolarUnited States, Ukraine, Bulgaria, Canada, Colombia, Russian Federation
-
Queen's UniversityPfizer; Providence Health & Services; MDS Pharma ServicesCompletedDepression, BipolarCanada
-
Ewha Womans University Mokdong HospitalWithdrawnDepression, BipolarKorea, Republic of
-
Mclean HospitalTerminatedBipolar Depression Depressed PhaseUnited States
-
AstraZenecaCompletedAcute Bipolar DepressionBrazil, Mexico, Peru, Turkey, Argentina, Chile, Venezuela, Colombia, Guatemala
-
Valerie TaylorUniversity Health Network, TorontoActive, not recruitingBipolar DepressionCanada
-
National University of Ireland, Galway, IrelandStanley Medical Research InstituteCompletedBipolar DepressionIreland
-
Astellas Pharma IncCompleted
Clinical Trials on Minocycline
-
Journey Medical CorporationDr. Reddy's Laboratories LimitedCompleted
-
State University of New York - Downstate Medical...RecruitingAsthma | Allergic RhinitisUnited States
-
Central South UniversityCompleted
-
OraPharmaCompleted
-
Rempex (a wholly owned subsidiary of Melinta Therapeutics...Innovative Medicines Initiative; Universitätsklinikum KölnTerminatedRenal Insufficiency, Chronic | Healthy Subjects | Renal Insufficiency, AcuteGermany
-
Johns Hopkins UniversityMakerere UniversityTerminatedHIV Infections | HIV-associated Cognitive ImpairmentUganda
-
University of PittsburghTerminated
-
Ain Shams Universityfaculty of pharmacy Tanta UniversityNot yet recruiting
-
University of South FloridaCompleted
-
Beijing Tiantan HospitalNeuroDawn Pharmaceutical Co., Ltd.RecruitingIschemic Stroke, AcuteChina